Latest Safety News

Imugene Limited has launched a $20 million capital raising through a $12 million institutional placement and an $8 million Share Purchase Plan, alongside a convertible notes amendment to support its clinical development pipeline.

WA Kaolin Limited has responded to ASX queries clarifying that its Q2 FY2026 order book was a demand snapshot, not a sales forecast, and confirmed timely disclosure of a production shortfall linked to plant issues. The company also addressed regulatory notices, affirming no material impact on operations or securities value.

Patrys has initiated manufacturing and regulatory steps for RLS-2201, its injectable Quetiapine formulation targeting delirium, aiming for Phase 0 trials in the second half of 2026.

Corazon Mining has contracted K-Drill to begin its first diamond drilling program at the Two Pools Gold Project in Western Australia, aiming to unlock high-grade gold potential and clarify complex geology.

King River Resources is deploying cutting-edge geophysical and digital mapping technologies at its historically rich Mindoolah Gold Project, aiming to unlock new high-grade gold targets with unprecedented precision.

Imugene Limited reports striking early results from its Phase 1b azer-cel trial, achieving a 100% overall response rate in chronic lymphocytic leukemia and 80% in marginal zone lymphoma, while broadening its study to include a BTK inhibitor combination.

OzAurum Resources has secured environmental approval for Stage 1 of its Mulgabbie North Gold Project, clearing a major regulatory hurdle and accelerating its path to near-term production.

Tetratherix Limited has raised approximately $5 million to fast-track its Tutelix prostate spacer into pivotal clinical trials across Australia and the US, aiming to improve radiation therapy for prostate cancer patients.

Aguia Resources has reported its best-ever gold production at the Santa Barbara project in Colombia, with metallurgical improvements driving recovery rates above 85%. The company is poised to achieve positive cash flow soon as it completes plant mechanisation and optimises mining operations.

Telix Pharmaceuticals has announced that Part 1 of its ProstACT Phase 3 trial for TLX591-Tx met its primary safety and dosimetry objectives, with no new safety concerns. The study’s success supports ongoing global enrolment in Part 2 and regulatory engagement in the US.

EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.

Pantoro Gold has reported a robust first half of FY2026 with record EBITDA and cash flow, while revising full-year production guidance due to weather and operational transitions. The appointment of Redpath as sole underground contractor signals a strategic move to streamline operations and support future growth.